Nous cherchons actuellement à parler à des oncologues pour un entretien téléphonique de 30 minutes sur le cancer du sein métastatique HER2+. Veuillez noter que les entretiens se dérouleront en anglais et que vous recevrez une prime de 75 EUR. Si vous souhaitez participer, veuillez-vous s’inscrire ici.
Actualmente estamos buscando hablar con los Oncólogos, vía una entrevista telefónica de 30 minutos sobre el cáncer de seno metastásico HER2 +. Tenga en cuenta que las entrevistas se realizarán en inglés. Inicie sesión o regístrese a continuación para participar en este estudio.
We are currently looking to speak with Oncologists, for a 30 minute telephone interview on the topic of HER2+ metastatic breast cancer. Please note that the interviews will be held in English. Please log in or sign up below to apply for this study.
We are looking to speak to Pulmonologists who will be attending the 2019 ERS Conference in Madrid. Please log in or sign up below to apply for this study.
We are looking to speak to Neurologists who have experience with treating CIDP and MMN. Please log in or sign up below to apply for this study.
We are looking for Pharmacists and Physicians in order to discuss a potential new anti-infective medication and get your feedback on certain aspects of it. Please log in or sign up below to apply for this study.
We are looking for Pathologists who would be interested in sharing their experience and opinions with us regarding the treatment of tumors. Please log in or sign up below to apply for this study.
We are looking for Medical Oncologists, Haemato-Oncologists, Pulmonologists and Respiratory Specialist who would be interested in sharing their experience and opinions with us regarding the treatment of tumors. Please log in or sign up below to apply for this study.
We are looking to speak to physicians who have experience with treatment of NUT Carcinoma patients in order to gain a deeper understanding of its management and treatment. Please log in or sign up below to apply for this study.
Les fiers membres et tenants de: